CJC-1295: Research Background and Overview

CJC-1295 is one of the more frequently referenced peptides in growth-hormone research, and also one of the more commonly misunderstood — largely because several closely related versions circulate under similar names. This overview clarifies what CJC-1295 is, how the variants differ, and what the research literature actually examines, strictly as a research-use-only reference compound. Nothing here concerns human or animal use, dosing, or outcomes.

What CJC-1295 is

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone (GHRH) — specifically a modified fragment of the GHRH sequence engineered for greater stability than the native peptide. In research contexts it's studied as a GHRH-receptor-targeting compound.

The name causes confusion because two forms are commonly discussed:

• CJC-1295 with DAC (Drug Affinity Complex): a version modified to bind albumin, extending its stability in experimental systems.
• CJC-1295 without DAC (often labeled "no-DAC," and closely related to the compound also called modified GRF 1-29): a shorter-acting version in research settings.

When a supplier lists "CJC-1295 no-DAC," they're referring to the version without the albumin-binding modification. Knowing which variant you're evaluating matters, because they behave differently in the literature.

What the research examines

The published literature on CJC-1295 — again, primarily cell-culture and animal-model work — examines it as a GHRH analog: how it interacts with the GHRH receptor, its stability relative to native GHRH, and its behavior in models of growth-hormone-axis signaling.

What the research does not establish — and what we won't imply — is any conclusion about effects in humans, any benefit, or any protocol. These are mechanistic findings in controlled research systems. They're the reason the compound remains a subject of study, not evidence of an outcome you can act on. As always, read the primary literature directly rather than relying on marketing claims.

Why purity and the COA matter here

CJC-1295 is a modified synthetic peptide, and small differences in synthesis and purity are exactly the kind of thing that shows up in the documentation, not the vial. For any research material, and this one especially:

1. Confirm independent third-party HPLC purity with mass-spec identity — this also confirms you're getting the variant you expect (no-DAC vs DAC).
2. Insist on a published, lot-specific Certificate of Analysis. If you're new to reading them, our guide on how to read a COA covers the three numbers that matter.
3. Check storage and handling guidance — see how to store peptides.

Sourcing it as a reference material

For readers sourcing research-grade reference compounds, CJC-1295 (no-DAC) is supplied as a research-use-only reference material by NovaForge Labs — third-party HPLC-tested with a published Certificate of Analysis, and supplied strictly for laboratory research use only, with no claims about use in people.

The short version

CJC-1295 is a stability-modified GHRH analog studied as a growth-hormone-axis research compound, and it comes in DAC and no-DAC forms that behave differently. Know which variant you're evaluating, read the primary research rather than the marketing, and — whatever you source — make the Certificate of Analysis the deciding factor.